Investors & Media

Multiple opportunities for immuno-oncology

Investors Home

Ziopharm Oncology is focused on advancing the next generation of immunotherapies to weaponize the existing immune system with Controlled IL-12 or introduce new immune system elements with Sleeping Beauty-modified T cells to this fight against cancer. In addition to developing the next generation of immuno-oncology medicines that target multiple types of cancers, we also are targeting the cost and complexity of delivering gene and cell therapies.

Ziopharm is focused on advancing the next generation of immunotherapies for patients and on delivering significant value for shareholders. The Board of Directors and Management Team urge shareholders to sign and return Ziopharm’s GREEN Consent Revocation Card.